News Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

End-of-day quote Euronext Paris Other stock markets 03:30:00 30/04/2024 am IST			5-day change	1st Jan Change
0.39 ^EUR	-4.88%		-89.79%	-86.55%

30/04	Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results	CI
26/04	Acticor Biotech: rebound from the previous day's tumble	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023	30/04	BU
Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results	30/04	CI
Acticor Biotech: rebound from the previous day's tumble	26/04	CF
Acticor Biotech: Phase 2/3 study fails	25/04	CF
ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment	25/04	BU
Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment	25/04	CI
Acticor Biotech: phase 2/3 results expected in May	16/04	CF
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024	15/04	BU
Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024	15/04	CI
Acticor Biotech: falls after capital increase	15/03	CF
Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	15/03	MT
Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros	15/03	BU
The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack	07/02	AQ
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack	07/02	CI
Acticor: 'we are delighted to observe the market's reaction'.	29/01	CF
Acticor Biotech continues to soar, hopes for stroke treatment	24/01	CF
Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal	23/01	CI
Acticor: capital increase at a significant discount	28/11	CF
Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	07/11	MT
Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke	07/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

Summary

Filters